Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy

  • PHASE I STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background The purposes of this study were to establish a novel blood pressure (BP) scoring method and to correlate it with clinical response in advanced cancer patients treated with anti-vascular endothelial growth factor (VEGF) therapies. Methods We retrospectively analyzed data for 368 patients from 23 clinical trials that included at least one anti-VEGF agent. We determined BP scores using the traditional Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and our novel method that considers both BP readings and number of anti-hypertensive medications the patient received. BP scores were categorized at baseline and four months. Logistic regression analysis correlated elevated scores with clinical response. Agreement between the CTCAE and the new method was assessed. Results Under the new BP scoring method, partial response rates were 20 % in patients with an elevated score at four months versus 6 % in patients without elevated score (P < 0.001). When adjusted for tumor type, age, sex, history of anti-VEGF treatment, and number of anti-VEGF treatments, elevated BP under the new scoring method had an odds ratio of 3.8 (95 % confidence interval [CI]: 1.8, 8.2; P < 0.001). The kappa statistic for agreement between the CTCAE and new scoring methods was 0.57 (95 % CI: 0.47, 0.67; P < 0.001), indicating significant concordance. Conclusion Using the novel scoring method, an increase in BP scores was a marker for favorable clinical response in patients who received anti-VEGF treatment. This new method ultimately provides information with regard to clinical tumor response over and above that provided by the CTCAE scoring method.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ichihara E, Kiura K, Tanimoto M (2011) Targeting angiogenesis in cancer therapy. Acta Med Okayama 65(6):353–362

    CAS  PubMed  Google Scholar 

  2. Folkman J (2006) Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 312(5):594–607. doi:10.1016/j.yexcr.2005.11.015

    Article  CAS  PubMed  Google Scholar 

  3. Linkous AG, Yazlovitskaya EM (2012) Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res 32(1):1–12

    CAS  PubMed  Google Scholar 

  4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60–65

    Article  CAS  PubMed  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi:10.1056/NEJMoa060655

    Article  CAS  PubMed  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044

    Article  CAS  PubMed  Google Scholar 

  7. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465–477. doi:10.1038/nrclinonc.2009.94

    Article  CAS  PubMed  Google Scholar 

  8. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117–123. doi:10.1016/S1470-2045(08)70003-2

    Article  CAS  PubMed  Google Scholar 

  9. Le Tourneau C, Raymond E, Faivre S (2007) Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 3(2):341–348

    Article  PubMed Central  PubMed  Google Scholar 

  10. Bergsland E, Dickler MN (2004) Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(Suppl 1):36–42

    Article  CAS  PubMed  Google Scholar 

  11. Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M (2012) Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 109(28):11306–11311. doi:10.1073/pnas.1203275109

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227–230. doi:10.1093/annonc/mdn637

    Article  CAS  PubMed  Google Scholar 

  13. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68(5):1207–1213. doi:10.1007/s00280-011-1604-1

    Article  PubMed  Google Scholar 

  14. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763–773. doi:10.1093/jnci/djr128

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Institute NC (2009) Common terminology criteria for adverse events v4.0 In Edition 2009

  16. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Luscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, Zanchetti A (2003) Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21(10):1779–1786. doi:10.1097/01.hjh.0000084773.37215.1b

    Article  CAS  PubMed  Google Scholar 

  17. Cuddy ML (2005) Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1). J Pract Nurs 55(4):17–21, quiz 22–13

    PubMed  Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  19. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16(9):1325–1332. doi:10.1634/theoncologist.2010-0002

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23(12):3180–3187. doi:10.1093/annonc/mds179

    Article  CAS  PubMed  Google Scholar 

  21. Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF (2011) Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol 60(2):344–349. doi:10.1016/j.eururo.2011.05.034

    Article  CAS  PubMed  Google Scholar 

  22. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638

    Article  PubMed Central  PubMed  Google Scholar 

  23. Powe DG, Entschladen F (2011) Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8(9):511–512. doi:10.1038/nrclinonc.2011.123

    Article  PubMed  Google Scholar 

  24. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645–2652. doi:10.1200/JCO.2010.33.4441

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939–944

    Article  CAS  PubMed  Google Scholar 

  26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart L, Blood Institute Joint National Committee on Prevention DE, Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA : J Am Med Assoc 289(19):2560–2572. doi:10.1001/jama.289.19.2560

    Article  CAS  Google Scholar 

  27. Zhang W, Li N (2011) Prevalence, risk factors, and management of prehypertension. Int J Hypertens 2011:605359. doi:10.4061/2011/605359

Download references

Acknowledgments

We acknowledge Sunita Patterson for scientific editing of the manuscript.

Disclosures

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Mehmet Asim Bilen

  2. Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jean-Bernard Durand & Michael S. Ewer

  3. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX, 77030, USA

    Lacey McQuinn, Siqing Fu, Gerald S. Falchook, David S. Hong, Jennifer J. Wheler & Aung Naing

  4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kenneth R. Hess

  5. Division of Internal Medicine-Oncology, The University of Texas Health Science Center, Houston, TX, USA

    Rabih Said

  6. Division of Hematology-Oncology, UC San Diego Moores Cancer Center, La Jolla, CA, USA

    Razelle Kurzrock

Authors
  1. Mehmet Asim Bilen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Bernard Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lacey McQuinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth R. Hess
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Siqing Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerald S. Falchook
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David S. Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jennifer J. Wheler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rabih Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael S. Ewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Razelle Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Aung Naing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aung Naing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bilen, M.A., Durand, JB., McQuinn, L. et al. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs 32, 717–722 (2014). https://doi.org/10.1007/s10637-014-0104-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-014-0104-7

Keywords

Search

Navigation